Regend Therapeutics is an innovative Biotech company in China. With the goal of "Reviving Life, Reshaping Health," we focus in the field of organ regeneration with progenitor cell-based regenerative medicine. After years of construction and development, we have established two preclinical research centers, an administrative headquarters, a GMP pilot research base, and a GMP progenitor cell production and storage base. This strategic layout achieves a complete industrial chain. In 2016, Regend Therapeutics was listed by the National Health Commission and the National Medical Products Administration into the first batch enterprises for stem cell clinical research projects. We were honored with the Second Prize of Jiangsu Province Medical Science and Technology Progress Award and selected as one of the "Top Ten Progresses in Medical Biotechnology" in 2018 in China. We have won nearly a hundred domestic awards until now. The phase I clinical trial result of our lung progenitor cell product REGEND001 on chronic obstructive pulmonary disease is elected as one of the top three annual progresses by the European Respiratory Society in 2023. The epithelial progenitor cell technology owned by Regend Therapeutics is domestically pioneering and internationally leading. Based on this, first in class lung progenitor cell product REGEND001 and kidney progenitor cell product REGEND003 have been developed. In the completed clinical trials, REGEND001 improved the gas transfer capacity, lung capacity, life quality, functional exercise capacity and other lung function measures of patients with various chronic pulmonary diseases. Astonishingly, REGEND001 successfully repaired their damaged lung structures, becoming the only drug that can regenerate lung in history: it diminished the emphysema lesions in chronic obstructive pulmonary disease, reduced the broncho-arterial ratio and inflammatory areas in bronchiectasis, and resolved the fibrotic tissues in idiopathic pulmonary fibrosis